ClinicalTrials.Veeva

Menu

What Are the Determinations of Adult Progressive CKD? The Renal Impairment In Secondary Care (RIISC) Study

U

University Hospital Birmingham NHS Foundation Trust

Status

Active, not recruiting

Conditions

Chronic Kidney Disease

Study type

Observational

Funder types

Other

Identifiers

NCT01722383
RRK3917

Details and patient eligibility

About

Chronic kidney disease (CKD) affects up to 16% of the adult population and is associated with significant morbidity and mortality. People at highest risk from progressive CKD are defined by a sustained decline in estimated glomerular filtration rate (eGFR) and/or the presence of significant albuminuria/proteinuria. Accurate mapping of the bio-clinical determinants of this group will enable improved risk stratification and direct the development of better targeted management for people with CKD. To address these requirements we have established the Renal Impairment in Secondary Care (RIISC) study; RIISC is enrolling a cohort of patients at high risk from progressive CKD and compiling a comprehensive and detailed bio-clinical phenotype, including vascular and oral health phenotyping, at enrolment and on subsequent follow-up.

Enrollment

932 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Decline of eGFR of ≥5mls/min/year or ≥10mls/min/5years
  • and/or urinary albumin-creatinine ration (ACR) ≥70 mg/mmol on three occasions
  • and/or CKD 4 or 5 (pre-dialysis)

Exclusion criteria

  • renal replacement therapy
  • immunosuppression

Trial design

932 participants in 1 patient group

Chronic kidney disease
Description:
Stages 3-5 chronic kidney disease (pre-dialysis)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems